Investment analysts at StockNews.com began coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP – Get Rating) in a research report issued on Monday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.
Titan Pharmaceuticals Trading Up 3.2 %
TTNP opened at $0.91 on Monday. Titan Pharmaceuticals has a one year low of $0.35 and a one year high of $1.59. The business’s 50-day simple moving average is $0.89 and its 200-day simple moving average is $1.10.
Institutional Trading of Titan Pharmaceuticals
Institutional investors have recently added to or reduced their stakes in the business. FNY Investment Advisers LLC purchased a new position in Titan Pharmaceuticals in the 3rd quarter valued at about $30,000. State Street Corp purchased a new position in Titan Pharmaceuticals in the 3rd quarter valued at about $41,000. Millennium Management LLC boosted its position in Titan Pharmaceuticals by 516.8% in the 2nd quarter. Millennium Management LLC now owns 63,106 shares of the specialty pharmaceutical company’s stock valued at $35,000 after buying an additional 52,874 shares during the last quarter. Virtu Financial LLC purchased a new position in Titan Pharmaceuticals in the 2nd quarter valued at about $35,000. Finally, Renaissance Technologies LLC boosted its position in Titan Pharmaceuticals by 559.3% in the 2nd quarter. Renaissance Technologies LLC now owns 240,710 shares of the specialty pharmaceutical company’s stock valued at $135,000 after buying an additional 204,200 shares during the last quarter. 32.45% of the stock is owned by hedge funds and other institutional investors.
About Titan Pharmaceuticals
Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in Canada and the European Union.
- Get a free copy of the StockNews.com research report on Titan Pharmaceuticals (TTNP)
- NVIDIA Outlook Improving: Watchlist Candidate for 2023
- Is C3.ai Stock a ChatGPT Artificial Intelligence Play?
- Which Wireless Stock Should You Buy in 2023?
- Is Virgin Galactic Stock Preparing for Lift-Off?
- Chevron is Likely to Increase its Dividend Before Earnings
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.